Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation
ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these v...
Gespeichert in:
Veröffentlicht in: | Journal of pharmacy and pharmacology 1999-02, Vol.51 (2), p.135-139 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 139 |
---|---|
container_issue | 2 |
container_start_page | 135 |
container_title | Journal of pharmacy and pharmacology |
container_volume | 51 |
creator | HOMER, KERRY L. FIORE, STEVEN A. WANSTALL, JANET C. |
description | ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO.
On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase.
NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response. |
doi_str_mv | 10.1211/0022357991772240 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69709870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69709870</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3620-416466239eae777c8d186a3f5a915cb80a710c0c61aa2fa9e5236299e66295433</originalsourceid><addsrcrecordid>eNpdkU1vEzEQhlcIREPhzgn5gBCVYvDHrh1zq9qSpJQkBFAPVWVNNrOKYWOn612R8LP4hewqASpOI8087ztfSfKcszdccP6WMSFkpo3hWguRsgdJT7BUUM2zwcOk15VpW5dHyZMYvzHGtFLqcXLEmeBact5Lfo39yi1c7YInix3hI3rD-6Kf3k63sHTwM5ThJu1LCrd3jfNhC6XzlNPgkbyenn86IaEgc4yb4CNGUgcycXXlcjLduiXSZfChisR5MoeazJpyHTxUO3Ja1Vjt3pGxL8oGfY6dTb1C8hHzFXgX113ivhUZoscKujmfJo8KKCM-O8Tj5Ov7iy9nI3o1HY7PTq-ok0owmnKVKiWkQUCtdT5Y8oECWWRgeJYvBgw0ZznLFQcQBRjMRKszBluRyVIpj5NXe99NFe4ajLVdu5hjWYLH0ESrjGZmoFkLvjiAzWKNS7up3Lrd0v65cgu8PAAQcyiLCnzu4j9OM21E1mLZHvvhStzds7Hds-3_z7aXs9EsNV1_ute5WOP2rw6q71ZpqTN7PRnaD9d6fqnOJ_az_A3i-ajU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69709870</pqid></control><display><type>article</type><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</creator><creatorcontrib>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</creatorcontrib><description>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO.
On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase.
NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</description><identifier>ISSN: 0022-3573</identifier><identifier>EISSN: 2042-7158</identifier><identifier>DOI: 10.1211/0022357991772240</identifier><identifier>PMID: 10217311</identifier><identifier>CODEN: JPPMAB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiovascular system ; Dose-Response Relationship, Drug ; Enzyme Inhibitors - pharmacology ; Guanylate Cyclase - antagonists & inhibitors ; Hydrazines - pharmacology ; In Vitro Techniques ; Male ; Medical sciences ; Molsidomine - analogs & derivatives ; Molsidomine - pharmacology ; Nitric Oxide - biosynthesis ; Nitric Oxide Donors - pharmacology ; Nitro Compounds - pharmacology ; Nitrogen Oxides ; Oxadiazoles - pharmacology ; Pharmacology. Drug treatments ; Pulmonary Artery - drug effects ; Pulmonary Artery - physiology ; Quinoxalines - pharmacology ; Rats ; Rats, Wistar ; Spermine - analogs & derivatives ; Spermine - pharmacology ; Vasodilation - drug effects</subject><ispartof>Journal of pharmacy and pharmacology, 1999-02, Vol.51 (2), p.135-139</ispartof><rights>1999 Royal Pharmaceutical Society of Great Britain</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1211%2F0022357991772240$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1211%2F0022357991772240$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1707925$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10217311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOMER, KERRY L.</creatorcontrib><creatorcontrib>FIORE, STEVEN A.</creatorcontrib><creatorcontrib>WANSTALL, JANET C.</creatorcontrib><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><title>Journal of pharmacy and pharmacology</title><addtitle>J Pharm Pharmacol</addtitle><description>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO.
On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase.
NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</description><subject>Animals</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Guanylate Cyclase - antagonists & inhibitors</subject><subject>Hydrazines - pharmacology</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molsidomine - analogs & derivatives</subject><subject>Molsidomine - pharmacology</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Nitro Compounds - pharmacology</subject><subject>Nitrogen Oxides</subject><subject>Oxadiazoles - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary Artery - drug effects</subject><subject>Pulmonary Artery - physiology</subject><subject>Quinoxalines - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Spermine - analogs & derivatives</subject><subject>Spermine - pharmacology</subject><subject>Vasodilation - drug effects</subject><issn>0022-3573</issn><issn>2042-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1vEzEQhlcIREPhzgn5gBCVYvDHrh1zq9qSpJQkBFAPVWVNNrOKYWOn612R8LP4hewqASpOI8087ztfSfKcszdccP6WMSFkpo3hWguRsgdJT7BUUM2zwcOk15VpW5dHyZMYvzHGtFLqcXLEmeBact5Lfo39yi1c7YInix3hI3rD-6Kf3k63sHTwM5ThJu1LCrd3jfNhC6XzlNPgkbyenn86IaEgc4yb4CNGUgcycXXlcjLduiXSZfChisR5MoeazJpyHTxUO3Ja1Vjt3pGxL8oGfY6dTb1C8hHzFXgX113ivhUZoscKujmfJo8KKCM-O8Tj5Ov7iy9nI3o1HY7PTq-ok0owmnKVKiWkQUCtdT5Y8oECWWRgeJYvBgw0ZznLFQcQBRjMRKszBluRyVIpj5NXe99NFe4ajLVdu5hjWYLH0ESrjGZmoFkLvjiAzWKNS7up3Lrd0v65cgu8PAAQcyiLCnzu4j9OM21E1mLZHvvhStzds7Hds-3_z7aXs9EsNV1_ute5WOP2rw6q71ZpqTN7PRnaD9d6fqnOJ_az_A3i-ajU</recordid><startdate>199902</startdate><enddate>199902</enddate><creator>HOMER, KERRY L.</creator><creator>FIORE, STEVEN A.</creator><creator>WANSTALL, JANET C.</creator><general>Blackwell Publishing Ltd</general><general>Pharmaceutical Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199902</creationdate><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><author>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3620-416466239eae777c8d186a3f5a915cb80a710c0c61aa2fa9e5236299e66295433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Guanylate Cyclase - antagonists & inhibitors</topic><topic>Hydrazines - pharmacology</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molsidomine - analogs & derivatives</topic><topic>Molsidomine - pharmacology</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Nitro Compounds - pharmacology</topic><topic>Nitrogen Oxides</topic><topic>Oxadiazoles - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary Artery - drug effects</topic><topic>Pulmonary Artery - physiology</topic><topic>Quinoxalines - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Spermine - analogs & derivatives</topic><topic>Spermine - pharmacology</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOMER, KERRY L.</creatorcontrib><creatorcontrib>FIORE, STEVEN A.</creatorcontrib><creatorcontrib>WANSTALL, JANET C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOMER, KERRY L.</au><au>FIORE, STEVEN A.</au><au>WANSTALL, JANET C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</atitle><jtitle>Journal of pharmacy and pharmacology</jtitle><addtitle>J Pharm Pharmacol</addtitle><date>1999-02</date><risdate>1999</risdate><volume>51</volume><issue>2</issue><spage>135</spage><epage>139</epage><pages>135-139</pages><issn>0022-3573</issn><eissn>2042-7158</eissn><coden>JPPMAB</coden><abstract>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO.
On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase.
NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10217311</pmid><doi>10.1211/0022357991772240</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3573 |
ispartof | Journal of pharmacy and pharmacology, 1999-02, Vol.51 (2), p.135-139 |
issn | 0022-3573 2042-7158 |
language | eng |
recordid | cdi_proquest_miscellaneous_69709870 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Animals Antianginal agents. Coronary vasodilator agents Biological and medical sciences Cardiovascular system Dose-Response Relationship, Drug Enzyme Inhibitors - pharmacology Guanylate Cyclase - antagonists & inhibitors Hydrazines - pharmacology In Vitro Techniques Male Medical sciences Molsidomine - analogs & derivatives Molsidomine - pharmacology Nitric Oxide - biosynthesis Nitric Oxide Donors - pharmacology Nitro Compounds - pharmacology Nitrogen Oxides Oxadiazoles - pharmacology Pharmacology. Drug treatments Pulmonary Artery - drug effects Pulmonary Artery - physiology Quinoxalines - pharmacology Rats Rats, Wistar Spermine - analogs & derivatives Spermine - pharmacology Vasodilation - drug effects |
title | Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20by%201H-%5B1,2,4%5DOxadiazolo%5B4,3-a%5Dquinoxalin-1-one%20(ODQ)%20of%20Responses%20to%20Nitric%20Oxide-donors%20in%20Rat%20Pulmonary%20Artery:%20Influence%20of%20the%20Mechanism%20of%20Nitric%20Oxide%20Generation&rft.jtitle=Journal%20of%20pharmacy%20and%20pharmacology&rft.au=HOMER,%20KERRY%20L.&rft.date=1999-02&rft.volume=51&rft.issue=2&rft.spage=135&rft.epage=139&rft.pages=135-139&rft.issn=0022-3573&rft.eissn=2042-7158&rft.coden=JPPMAB&rft_id=info:doi/10.1211/0022357991772240&rft_dat=%3Cproquest_pubme%3E69709870%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69709870&rft_id=info:pmid/10217311&rfr_iscdi=true |